Status In progress
Process STA
ID number 671

Provisional Schedule

Expected publication June 2017

Project Team

Project lead Stephanie Yates

Email enquiries

Consultees

Companies sponsors Incyte Corporation (ponatinib)
Others Department of Health
  NHS England
Patient carer groups Chronic Myeloid Leukaemia Support Group
  Leukaemia CARE
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians

Commentators

Associated public health groups None
Comparator companies Bristol-Myers Squibb (hydroxycarbamide) (no confidentiality agreement signed, not participating)
  Medac UK (hydroxycarbamide)(no confidentiality agreement signed, not participating)
  Nordic Pharma (hydroxycarbamide)(no confidentiality agreement signed, not participating)
  Pfizer (bosutinib)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
16 March 2017 Committee meeting: 2
13 February 2017 - 06 March 2017 Appraisal consultation: 1
18 January 2017 Committee meeting: 1
15 August 2016 Invitation to participate
27 June 2016 Draft scope documents

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance